TrialA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Trial details
- Registry ID
- NCT05506943
- Phase
- Phase 2, Phase 3
Drug research
CTX-009
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943 | Compass Therapeutics | Phase 2, Phase 3 | Active not recruiting | 2027-08-31Estimated |
| A Study of CTX-009 in Adult Patients With Metastatic Colorectal CancerNCT05513742 | Compass Therapeutics | Phase 2 | Completed | 2025-05-15Actual |
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
Trial details
- Registry ID
- NCT05513742
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |